

Pipeline Looks Full of New Osteoporosis Therapies

BY ROBERT FINN
San Francisco Bureau

SAN FRANCISCO — “It’s a pretty exciting time for drug development in osteoporosis,” Dr. Deborah Sellmeyer said at a meeting on osteoporosis sponsored by the University of California, San Francisco.

While joking that her information was “sourced from Google and rumor and various investment brochures,” Dr. Sellmeyer, director of the Center for Osteo-

porosis at the university, listed some of the osteoporosis drugs in the pipeline.

A fracture trial for a full-length version of parathyroid hormone (PTH [1-84]) has been completed, and a new drug application (NDA) was submitted to the Food and Drug Administration in July 2005. “The latest rumors are that there needs to be little more safety data coming in before that one’s going to go much further,” she said.

Meanwhile, inhaled-powder and oral forms of PTH are in phase I and phase II

trials, and at least one PTH analogue is in phase III. “Everyone’s looking for the magic combination that will be able to replicate the PTH skeletal effect and get rid of the hypercalcemic effect.”

Oral calcitonin preparations are in phase I and phase II. And low-dose and ultralow-dose estrogen remain fertile areas of research. The hope is that these preparations will replicate the beneficial bone effects of estrogen while avoiding its harmful vascular effects. Although two low-dose patches

and one low-dose pill have already been approved for the prevention of osteoporosis and for the treatment of vasomotor symptoms, no fracture data are yet available.

Zoledronic acid, a once-a-year intravenous bisphosphonate, is approved for hypercalcemia of malignancy and is now in a phase III trial to determine whether it prevents osteoporotic fractures. This agent is likely to benefit people who cannot tolerate oral bisphosphonates, people in assisted-living situations, and people who have difficulty remembering to take medication.

There are several new selective estrogen receptor modulators under development, with three—lasofoxifene, bazedoxifene, and arzoxifene—in phase III or beyond. An NDA for lasofoxifene was submitted to the FDA in 2004, but the manufacturer apparently received a nonapprovable letter in September 2005, putting the drug in limbo. An NDA for bazedoxifene has been submitted for the prevention of osteoporosis, and an NDA is planned for 2007 for a combination of bazedoxifene and estrogen for osteoporosis treatment and possible premenopausal use. Results from a phase III trial of arzoxifene are expected in 2010.

Tibolone is a drug that “likes every steroid receptor it ever met,” in Dr. Sellmeyer’s words. Its three metabolites separately have affinities for estrogen, progesterone, and androgen receptors. A recently completed 24-month prevention trial in 90 women showed no difference in vaginal spotting between tibolone and placebo. Interestingly, the women taking placebo experienced a 12% weight gain, whereas those taking tibolone experienced no average weight gain. A multinational fracture study involving 4,000 women is expected to conclude sometime this year.

It’s been known for decades that strontium improves bone mineral density (BMD), but it was never developed for osteoporosis prevention or treatment because it’s a nonpatentable chemical element. Recently, however, a proprietary formulation of strontium—strontium ranelate—has shown some promise. A granular form has already been approved for use in Europe and the United Kingdom, and a once-a-day pill finished a phase I trial in September 2005. Strontium ranelate is likely to complicate interpretation of BMD testing because it has a higher density than calcium.

Denosumab, or AMG 162, is a monoclonal antibody that seems to lower bone resorption. Currently in a phase III fracture trial on postmenopausal women, it will require two subcutaneous injections per year.

Isosorbide mononitrate, long used for the pain of angina, appears to improve several bone markers in postmenopausal women. A BMD trial is underway.

In one study, the combination of folate and vitamin B₁₂ greatly decreased the incidence of hip fractures, but it involved patients who experienced stroke and hemiplegia. If this combination proves equally efficacious in other populations, it would provide a remarkably inexpensive and safe intervention for osteoporosis. Finally, β -blockers constitute another class of drugs that may have bone effects, but random trials are needed to establish whether they have a place in osteoporosis therapy. ■

CHANTIXTM (varenicline) TABLETS

INDICATIONS AND USAGE

CHANTIX is indicated as an aid to smoking cessation treatment.

PRECAUTIONS

General. Nausea was the most common adverse event associated with CHANTIX treatment. Nausea was generally described as mild or moderate and often transient; however, for some subjects, it was persistent over several months. The incidence of nausea was dose-dependent. Initial dose-titration was beneficial in reducing the occurrence of nausea. Nausea was reported by approximately 30% of patients treated with CHANTIX 1 mg BID after an initial week of dose titration. In patients taking CHANTIX 0.5 mg BID, the incidence of nausea was 16% following initial titration. Approximately 3% of subjects treated with CHANTIX 1 mg BID in studies involving 12 weeks of treatment discontinued treatment prematurely because of nausea. For patients with intolerable nausea, dose reduction should be considered. **Effect of smoking cessation:** Physiological changes resulting from smoking cessation, with or without treatment with CHANTIX, may alter the pharmacokinetics or pharmacodynamics of some drugs, for which dosage adjustment may be necessary (examples include theophylline, warfarin and insulin).

Drug Interactions. Based on varenicline characteristics and clinical experience to date, CHANTIX has no clinically meaningful pharmacokinetic drug interactions (See **Full Prescribing Information, CLINICAL PHARMACOLOGY, Drug-Drug Interactions**).

Carcinogenesis, Mutagenesis, Impairment of Fertility. Carcinogenesis. Lifetime carcinogenicity studies were performed in CD-1 mice and Sprague-Dawley rats. There was no evidence of a carcinogenic effect in mice administered varenicline by oral gavage for 2 years at doses up to 20 mg/kg/day (47 times the maximum recommended human daily exposure based on AUC). Rats were administered varenicline (1, 5, and 15 mg/kg/day) by oral gavage for 2 years. In male rats (n = 65 per sex per dose group), incidences of hibernoma (tumor of the brown fat) were increased at the mid dose (1 tumor, 5 mg/kg/day, 23 times the maximum recommended human daily exposure based on AUC) and maximum dose (2 tumors, 15 mg/kg/day, 67 times the maximum recommended human daily exposure based on AUC). The clinical relevance of this finding to humans has not been established. There was no evidence of carcinogenicity in female rats.

Mutagenesis. Varenicline was not genotoxic, with or without metabolic activation, in the following assays: Ames bacterial mutation assay; mammalian CHO/HGPRT assay; and tests for cytogenetic aberrations *in vivo* in rat bone marrow and *in vitro* in human lymphocytes.

Impairment of fertility. There was no evidence of impairment of fertility in either male or female Sprague-Dawley rats administered varenicline succinate up to 15 mg/kg/day (67 and 36 times, respectively, the maximum recommended human daily exposure based on AUC at 1 mg BID). However, a decrease in fertility was noted in the offspring of pregnant rats who were administered varenicline succinate at an oral dose of 15 mg/kg/day (36 times the maximum recommended human daily exposure based on AUC at 1 mg BID). This decrease in fertility in the offspring of treated female rats was not evident at an oral dose of 3 mg/kg/day (9 times the maximum recommended human daily exposure based on AUC at 1 mg BID).

Pregnancy. Pregnancy Category C. Varenicline succinate was not teratogenic in rats and rabbits at oral doses up to 15 and 30 mg/kg/day, respectively (36 and 50-times the maximum recommended human daily exposure based on AUC at 1 mg BID, respectively). **Nonteratogenic effects.** Varenicline succinate has been shown to have an adverse effect on the fetus in animal reproduction studies. Administration of varenicline succinate to pregnant rabbits resulted in reduced fetal weights at an oral dose of 30 mg/kg/day (50 times the human AUC at 1 mg BID); this reduction was not evident following treatment with 10 mg/kg/day (23 times the maximum recommended daily human exposure based on AUC). In addition, in the offspring of pregnant rats treated with varenicline succinate there were decreases in fertility and increases in auditory startle response at an oral dose of 15 mg/kg/day (36 times the maximum recommended human daily exposure based on AUC at 1 mg BID). There are no adequate and well-controlled studies in pregnant women. CHANTIX should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. **Nursing mothers.** Although it is not known whether this drug is excreted in human milk, animal studies have demonstrated that varenicline can be transferred to nursing pups. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from CHANTIX, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. **Labor and delivery.** The potential effects of CHANTIX on labor and delivery are not known. **Pediatric Use.** Safety and effectiveness of CHANTIX in pediatric patients have not been established; therefore, CHANTIX is not recommended for use in patients under 18 years of age. **Geriatric Use.** A combined single and multiple-dose pharmacokinetic study demonstrated that the pharmacokinetics of 1 mg varenicline given QD or BID to 16 healthy elderly male and female smokers (aged 65-75 yrs) for 7 consecutive days was similar to that of younger subjects. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. Varenicline is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function (see **DOSE AND ADMINISTRATION, Special Populations, Patients with impaired renal function**). No dosage adjustment is recommended for elderly patients (see **DOSE AND ADMINISTRATION, Special Populations**).

Information for Patients:

- Patients should be instructed to set a date to quit smoking and to initiate CHANTIX treatment one week before the quit date.
- Patients should be instructed that CHANTIX should be taken after eating, and with a full glass of water.
- Patients should be instructed how to titrate CHANTIX, beginning at a dose of 0.5 mg/day. Prescribers should explain that one 0.5 mg tablet should be taken daily for the first three days, and that for the next four days, one 0.5 mg tablet should be taken in the morning and one 0.5 mg tablet should be taken in the evening.
- Patients should be advised that, after the first seven days, the dose should be increased to one 1 mg tablet in the morning and one 1 mg tablet in the evening.
- Patients should be encouraged to continue to attempt to quit if they have early lapses after quit day.
- Patients should be informed that nausea and insomnia are side effects of CHANTIX and are usually transient; however, patients should be advised that if they are persistently troubled by these symptoms, they should notify the prescribing physician so that a dose reduction can be considered.
- Patients should also be provided with educational materials and necessary counseling to support an attempt at quitting smoking.
- Patients should be informed that some medications may require dose adjustment after quitting smoking.
- Patients intending to become pregnant or planning to breast-feed an infant should be advised of the risks of smoking and risks and benefits of smoking cessation with CHANTIX.

ADVERSE REACTIONS

During the premarketing development of CHANTIX, over 4500 individuals were exposed to CHANTIX, with over 450 treated for at least 24 weeks and approximately 100 for a year. Most study participants were treated for 12 weeks or less. In Phase 2 and 3 placebo-controlled studies, the treatment discontinuation rate due to adverse events in patients dosed with 1 mg BID was 12% for CHANTIX compared to 10% for placebo in studies of three months’ treatment. In this group, the discontinuation rates for the most common adverse events in CHANTIX treated patients were as follows: nausea (3% vs. 0.5% for placebo), headache (0.6% vs. 0.9% for placebo), insomnia (1.2% vs. 1.1% for placebo), and abnormal dreams (0.3% vs. 0.2% for placebo). Adverse Events were categorized using the Medical Dictionary for Regulatory Activities (MedDRA, Version 7.1).

The most common adverse events associated with CHANTIX (p=5 and twice the rate seen in placebo-treated patients) were nausea, sleep disturbance, constipation, flatulence, and vomiting. Smoking cessation, with or without treatment, is associated with nicotine withdrawal symptoms.

The most common adverse event associated with CHANTIX treatment is nausea. For patients treated to the maximum recommended dose of 1 mg BID following initial dosage titration, the incidence of nausea was 30% compared with 10% in patients taking a comparable placebo regimen. In patients taking CHANTIX 0.5 mg BID following initial titration, the incidence was 16% compared with 11% for placebo. Nausea was generally described as mild or moderate and often transient; however, for some subjects, it was persistent throughout the treatment period.

Table 3 shows the adverse events for CHANTIX and placebo in the 12 week fixed dose studies with titration in the first week (Studies 2 (titrated arm only), 4, and 5). MedDRA High Level Group Terms (HLGT) reported in $\geq 5\%$ of patients in the CHANTIX 1 mg BID dose group, and more commonly than in the placebo group, are listed, along with subordinate Preferred Terms (PT) reported in $\geq 1\%$ of CHANTIX patients (and at least 0.5% more frequent than placebo). Closely related Preferred Terms such as “Insomnia”, “Initial insomnia”, “Middle insomnia”, “Early morning awakening” were grouped, but individual patients reporting two or more grouped events are only counted once.

Table 3: Common Treatment Emergent AEs (%) in the Fixed-Dose, Placebo-Controlled Studies ($\geq 1\%$ in the 1 mg BID CHANTIX Group, and 1 mg BID CHANTIX at least 0.5% more than Placebo)

SYSTEM ORGAN CLASS High Level Group Term Preferred Term	CHANTIX 0.5 mg BID N=129	CHANTIX 1mg 1mg BID N=821	Placebo N=805
GASTROINTESTINAL			
GI Signs and Symptoms			
Nausea	16	30	10
Abdominal Pain*	7	5	5
Flatulence	5	6	3
Dyspepsia	5	5	3
Vomiting	1	5	2
GI Motility/Defecation Conditions			
Constipation	5	8	3
Gastroesophageal reflux disease	1	1	0
Salivary Gland Conditions			
Dry mouth	4	6	4



Before prescribing, please consult
Full Prescribing Information.

(Table 3 continued)

PSYCHIATRIC DISORDERS			
Sleep Disorders/Disturbances			
Insomnia**	19	18	13
Abnormal dreams	9	13	5
Sleep disorder	2	5	3
Nightmare	2	1	0
NERVOUS SYSTEM			
Headaches			
Headache	19	15	13
Neurological Disorders NEC			
Dysgeusia	8	5	4
Somnolence	3	3	2
Lethargy	2	1	0
GENERAL DISORDERS			
General Disorders NEC			
Fatigue/Malaise/Asthenia	4	7	6
RESPIRATORY/THORACIC/MEDIAST			
Respiratory Disorders NEC			
Rhinorrhea	0	1	0
Dyspnea	2	1	1
Upper Respiratory Tract Disorder	7	5	4
SKIN/SUBCUTANEOUS TISSUE			
Epidermal and Dermal Conditions			
Rash	1	3	2
Pruritus	0	1	1
METABOLISM & NUTRITION			
Appetite/General Nutrit. Disorders			
Increased appetite	4	3	2
Decreased appetite/Anorexia	1	2	1

* Includes PTs Abdominal (pain, pain upper, pain lower, discomfort, tenderness, distension) and Stomach discomfort
** Includes PTs Insomnia/Initial insomnia/Middle insomnia/Early morning awakening

The overall pattern, and the frequency of adverse events during the longer-term trials was very similar to that described in Table 3, though several of the most common events were reported by a greater proportion of patients. Nausea, for instance, was reported in 40% of patients treated with CHANTIX 1 mg BID in a one-year study, compared to 8% of placebo-treated patients.

Following is a list of treatment-emergent adverse events reported by patients treated with CHANTIX during all clinical trials. The listing does not include those events already listed in the previous tables or elsewhere in labeling, those events for which a drug cause was remote, those events which were so general as to be uninformative, and those events reported only once which did not have a substantial probability of being acutely life-threatening. **BLOOD AND LYMPHATIC SYSTEM DISORDERS.** **Infrequent:** Anemia, Lymphadenopathy. **Rare:** Leukocytosis, Thrombocytopenia, Splenomegaly. **CARDIAC DISORDERS.** **Infrequent:** Angina pectoris, Arrhythmia, Bradycardia, Ventricular extrasystoles, Myocardial infarction, Palpitations, Tachycardia. **Rare:** Atrial fibrillation, Cardiac flutter, Coronary artery disease, Cor pulmonale, Acute coronary syndrome. **EAR AND LABYRINTH DISORDERS.** **Infrequent:** Tinnitus, Vertigo. **Rare:** Deafness, Meniere’s disease. **ENDOCRINE DISORDERS.** **Infrequent:** Thyroid gland disorders. **EYE DISORDERS.** **Infrequent:** Conjunctivitis, Dry eye, Eye irritation, Vision blurred, Visual disturbance, Eye pain. **Rare:** Acquired night blindness, Blindness transient, Cataract subcapsular, Ocular vascular disorder, Photophobia, Vitreous floaters. **GASTROINTESTINAL DISORDERS.** **Frequent:** Diarrhea, Gingivitis. **Infrequent:** Dysphagia, Enterocolitis, Eructation, Gastritis, Gastrointestinal hemorrhage, Mouth ulceration, Esophagitis. **Rare:** Gastric ulcer, Intestinal obstruction, Pancreatitis acute. **GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS.** **Frequent:** Chest pain, influenza like illness, Edema, Thirst. **Infrequent:** Chest discomfort, Chills, Pyrexia. **HEPATOBIILIARY DISORDERS.** **Infrequent:** Gall bladder disorder. **IMMUNE SYSTEM DISORDERS.** **Infrequent:** Hypersensitivity. **Rare:** Drug hypersensitivity. **INVESTIGATIONS.** **Frequent:** Liver function test abnormal, Weight increased. **Infrequent:** Electrocardiogram abnormal, Muscle enzyme increased, Urine analysis abnormal. **METABOLISM AND NUTRITION DISORDERS.** **Infrequent:** Diabetes mellitus, Hyperlipidemia, Hypokalemia. **Rare:** Hyperkalemia, Hypoglycemia. **MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS.** **Infrequent:** Arthralgia, Back pain, Muscle cramp, Musculoskeletal pain, Myalgia. **Infrequent:** Arthritis, Osteoporosis. **Rare:** Myositis. **NERVOUS SYSTEM DISORDERS.** **Infrequent:** Disturbance in attention, Dizziness, Sensory disturbance. **Infrequent:** Amnesia, Migraine, Parosmia, Psychomotor hyperactivity, Restless legs syndrome, Syncope, Tremor. **Rare:** Balance disorder, Cerebrovascular accident, Convulsion, Dysarthria, Facial palsy, Mental impairment, Multiple sclerosis, Nystagmus, Psychomotor skills impaired, Transient ischemic attack, Visual field defect. **PSYCHIATRIC DISORDERS.** **Frequent:** Anxiety disorder, Depression, Emotional disorder, Irritability, Restlessness. **Infrequent:** Aggression, Agitation, Disorientation, Dissociation, Libido decreased, Mood swings, Thinking abnormal. **Rare:** Bradypnea, Euphoric mood, Hallucination, Psychotic disorder, Suicidal ideation. **RENAL AND URINARY DISORDERS.** **Frequent:** Polyuria. **Infrequent:** Nephrolithiasis, Nocturia, Urine abnormality, Urinary syndrome. **Rare:** Renal failure acute, Urinary retention. **REPRODUCTIVE SYSTEM AND BREAST DISORDERS.** **Frequent:** Menstrual disorder. **Infrequent:** Erectile dysfunction. **Rare:** Sexual dysfunction. **RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS.** **Frequent:** Epistaxis, Respiratory disorders. **Infrequent:** Asthma, Atelectasis, Pulmonary embolism. **SKIN AND SUBCUTANEOUS TISSUE DISORDERS.** **Frequent:** Hyperhidrosis. **Infrequent:** Acne, Dermatitis, Dry skin, Eczema, Erythema, Psoriasis, Urticaria. **Rare:** Photosensitivity reaction. **VASCULAR DISORDERS.** **Frequent:** Hot flush, Hypertension. **Infrequent:** Hypotension, Peripheral ischemia, Thrombosis.

DRUG ABUSE AND DEPENDENCE

Controlled Substance Class. Varenicline is not a controlled substance. **Humans:** Fewer than 1 out of 1000 patients reported euphoria in clinical trials with CHANTIX. At higher doses (greater than 2 mg), CHANTIX produced more frequent reports of gastrointestinal disturbances such as nausea and vomiting. There is no evidence of dose-escalation to maintain therapeutic effects in clinical studies, which suggests that tolerance does not develop. Abrupt discontinuation of CHANTIX was associated with an increase in irritability and sleep disturbances in up to 3% of patients. This suggests that, in some patients, varenicline may produce mild physical dependence which is not associated with addiction. In a human laboratory abuse liability study, a single oral dose of 1 mg varenicline did not produce any significant positive or negative subjective responses in smokers. In non-smokers, 1 mg varenicline produced an increase in some positive subjective effects, but this was accompanied by an increase in negative adverse effects, especially nausea. A single oral dose of 3 mg varenicline uniformly produced unpleasant subjective responses in both smokers and non-smokers. **Animals:** Studies in rodents have shown that varenicline produced behavioral responses similar to those produced by nicotine. In rats trained to discriminate nicotine from saline, varenicline produced full generalization to the nicotine cue. In self-administration studies, the degree to which varenicline substitutes for nicotine is dependent upon the requirement of the task. Rats trained to self-administer nicotine under easy conditions continued to self-administer varenicline to a degree comparable to that of nicotine, however in a more demanding task, rats self-administered varenicline to a lesser extent than nicotine. Varenicline pretreatment also reduced nicotine self-administration.

OVERDOSAGE

In case of overdose, standard supportive measures should be instituted as required. Varenicline has been shown to be dialyzed in patients with end stage renal disease (see **Full Prescribing Information, CLINICAL PHARMACOLOGY, Pharmacokinetics, Pharmacokinetics in Special Patient Populations**); however, there is no experience in dialysis following overdose.

DOSE AND ADMINISTRATION

Usual Dosage for Adults. Smoking cessation therapies are more likely to succeed for patients who are motivated to stop smoking and who are provided additional advice and support. Patients should be provided with appropriate educational materials and counseling to support the quit attempt. The patient should set a date to stop smoking. CHANTIX dosing should start one week before this date. CHANTIX should be taken after eating and with a full glass of water. The recommended dose of CHANTIX is 1 mg twice daily following a 1-week titration as follows:

Days 1–3:	0.5 mg once daily
Days 4–7:	0.5 mg twice daily
Days 8–End of treatment:	1 mg twice daily

Patients who cannot tolerate adverse effects of CHANTIX may have the dose lowered temporarily or permanently. Patients should be treated with CHANTIX for 12 weeks. For patients who have successfully stopped smoking at the end of 12 weeks, an additional course of 12 weeks treatment with CHANTIX is recommended to further increase the likelihood of long-term abstinence. Patients who do not succeed in stopping smoking during 12 weeks of initial therapy, or who relapse after treatment, should be encouraged to make another attempt once factors contributing to the failed attempt have been identified and addressed.

Special Populations

Patients with impaired renal function. No dosage adjustment is necessary for patients with mild to moderate renal impairment. For patients with severe renal impairment, the recommended starting dose of CHANTIX is 0.5 mg once daily. Patients may then titrate as needed to a maximum dose of 0.5 mg twice a day. For patients with end-stage renal disease undergoing hemodialysis, a maximum dose of 0.5 mg once daily may be administered if tolerated well (See **Full Prescribing Information, CLINICAL PHARMACOLOGY, Pharmacokinetics in Special Populations, Renal impairment**). **Dosing in elderly patients and patients with impaired hepatic function.** No dosage adjustment is necessary for patients with hepatic impairment. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function (See **PRECAUTIONS, Geriatric Use**). **Use in children.** Safety and effectiveness of CHANTIX in pediatric patients have not been established; therefore, CHANTIX is not recommended for use in patients under 18 years of age.